REPLi: Identify Prot​​​​​​​​​​​​​​ease Substrates

Do you have an unidentified protease? Do you want to know its target sequence?

A Rapid Endopeptidase Profiling Library (REPLi) is a generic Fluorescent Resonance Energy Transfer (FRET) Peptide Library designed specifically to overcome common hurdles and simplify the protease profiling process. Mimotopes’ REPLi Library is available off-the-shelf and ready to use from our online catalogue.

Find out more

REPLi Requirements

An advantage of REPLi is it doesn’t require any prior knowledge of the proteases under investigation to help define the sequence of the protease cleavage site.

This peptide library comprises 3375 peptides divided into 512 distinct pools, each containing only 8 peptides so it can be rapidly deconvoluted to identify the specific sequences cleaved by your proteases.

Proteases are valuable drug targets in disease treatment, therefore fast identification of protease substrates directly from cells and tissues is invaluable.

How FRET Functions

FRET is commonly used to investigate protein interactions, including proteolysis.

In REPLi, the tripeptide core sequence is book-ended by glycine residues, with a fluorescent donor and quenching acceptor on opposite ends. When proteases cleave the peptide sequence, the quenching effect ends and the donor fluoresces.

Through real time proteolytic activity monitoring, this peptide library design provides a quantitative measure of the differences in substrate processing of low-abundant proteins, as disease markers.

Is REPLi Reliable?

Validation studies with well-characterised representative proteases from each of the four mechanistic protease classes have shown the impressively specific and sensitive capabilities of REPLi.

Results obtained from REPLi can be followed up with precise directed analysis using purified custom peptides or peptide libraries.

CONTACT US TODAY

for a peptide quote! 

☎ +61 3 9565 1111

✉ australia@mimotopes.com

☎ +1 651 603 0909

 useast@mimotopes.com

☎ +61 3 9565 1111

✉ asia@mimotopes.com

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

 for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | What's in a nameGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Lactalis IngredientsGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: BEA TechnologiesGo to article: NatoliGo to article: In DepthGo to article: What’s in a name: Agencies struggle to keep up with new drug names Go to article: How gene therapies can transform sickle cell disease treatment Go to article: Childproof packaging: How things are changing for consumer drugsGo to article: BIO-Europe 2023: Pharma balances on shaky financial and legislative footingGo to article: Reform in South Korea means progression in improving time to reimbursement Go to article: Q&A: UK pharma manufacturing prepares for imminent shake up in 2024 Go to article: Bio Image SystemsGo to article: PfanstiehlGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue